ライフサイエンスコーパス: intraepithelial neoplasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tal intraepithelial neoplasias (eg, cervical intraepithelial neoplasia).

2 e without affecting hyperplasia or prostatic intraepithelial neoplasia.

3 yperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia.

4 fficient to induce hyperplasia and prostatic intraepithelial neoplasia.

5 ulation, leading to development of prostatic intraepithelial neoplasia.

6 arly as at the stage of high-grade prostatic intraepithelial neoplasia.

7 ve to surgery in female patients with vulval intraepithelial neoplasia.

8 results showed that 4 eyes had conjunctival intraepithelial neoplasia.

9 oliferation, hyperplasia, and early prostate intraepithelial neoplasia.

10 n Dist-Luminal-C cells resulted in prostatic intraepithelial neoplasia.

11 cifically overexpress ETV1 develop prostatic intraepithelial neoplasia.

12 pancreatic ducts, referred to as pancreatic intraepithelial neoplasias.

13 mice, but did not alter growth of pancreatic intraepithelial neoplasias.

14 grade dysplasia and some enlarged pancreatic intraepithelial neoplasias.

15 etaplasia, dysplasia, and ultimately gastric intraepithelial neoplasias.

16 papillary mucinous neoplasms and in multiple intraepithelial neoplasias.

17 and tolerable for treating usual-type vulvar intraepithelial neoplasia?

18 n of oncogenic KRAS, premalignant pancreatic intraepithelial neoplasia 1 (PanIN1) lesions rarely beco

19 ntial reduction of ADM as well as pancreatic intraepithelial neoplasia-1 (PanIN-1), PanIN-2, and PanI

20 Its expression is lost at the pancreatic intraepithelial neoplasia 1b (PanIN1b)/PanIN2 stage of p

21 ting premalignant cervical lesions (cervical intraepithelial neoplasia 2+ [CIN2+]) is an effective wa

22 e 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ

23 Development of cervical intraepithelial neoplasia 2/3 was rare in women with red

24 ening algorithm found more disease (cervical intraepithelial neoplasia 3 or worse [CIN3+]) and also f

25 I, 1.67 to 3.31); grade 2 or higher cervical intraepithelial neoplasia, 6.9% vs. 3.4% (hazard ratio,

26 (2 benign papillomas, 2 grade 2 conjunctival intraepithelial neoplasias, 7 in situ squamous carcinoma

27 s to surgery for female patients with vulval intraepithelial neoplasia after exclusion of occult inva

28 amous intraepithelial lesions (ASIL) or anal intraepithelial neoplasia (AIN) are precancerous lesions

29 High-grade anal intraepithelial neoplasia (AIN) is present in many human

30 -related factors on anal HPV infection, anal intraepithelial neoplasia (AIN), and anal cancer among p

31 High-grade anal intraepithelial neoplasia (AIN2/3; HGAIN) is highly prev

32 ients, including 11 low-grade, 14 high-grade intraepithelial neoplasia and 12 invasive carcinoma in 3

33 ped an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumor

34 lly classified as benign prostate, prostatic intraepithelial neoplasia and adenocarcinoma, can be eva

35 normal mammary epithelium, developed ductal intraepithelial neoplasia and DCIS, and progressed to in

36 (Fl/Fl)) failed to progress beyond prostatic intraepithelial neoplasia and did not harbor genomic CNA

37 es local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical ca

38 diminished SC chemoattraction to pancreatic intraepithelial neoplasia and increased abdominal hypers

39 ations showed that the severity of prostatic intraepithelial neoplasia and inflammation development g

40 levels of H3K27me3 are reduced in prostatic intraepithelial neoplasia and invasive adenocarcinoma le

41 low but increases significantly in cervical intraepithelial neoplasia and invasive squamous cervical

42 with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa.

43 reased significantly in high-grade prostatic intraepithelial neoplasia and PCa.

44 ls in culture and for Kras-driven pancreatic intraepithelial neoplasia and PDAC formation in vivo.

45 n littermates developed high-grade prostatic intraepithelial neoplasia and prostate cancer.

46 ith c-myc overexpression to induce prostatic intraepithelial neoplasia and prostate cancer.

47 that Olfm4-knockout mice developed prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

48 l, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostat

49 , safe, and feasible for treatment of vulval intraepithelial neoplasia and warrant further investigat

50 ho received RFA for BE containing high-grade intraepithelial neoplasia and/or early-stage cancer for

51 rrett's esophagus (BE) containing high-grade intraepithelial neoplasia and/or early-stage cancer.

52 as HPV DNA is detected in up to 90% of anal intraepithelial neoplasias and anal cancers.

53 ns, but progression to high-grade pancreatic intraepithelial neoplasias and PDAC is blocked.

54 and RAC1 were increased in human pancreatic intraepithelial neoplasias and PDAs compared with health

55 rom the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma

56 mation of precancerous lesions (endometrioid intraepithelial neoplasia) and well-differentiated endom

57 6% for PAM, 67% for conjunctival melanocytic intraepithelial neoplasia, and 81% for WHO classificatio

58 expression of Bmi1 in mice induced prostatic intraepithelial neoplasia, and elicited invasive adenoca

59 eads to the formation of kidney cysts, renal intraepithelial neoplasia, and invasive papillary renal

60 ation systems: PAM, conjunctival melanocytic intraepithelial neoplasia, and the WHO 4th edition class

61 decreased formation of high-grade pancreatic intraepithelial neoplasias, and accelerated development

62 y analyzed for formation of IPMN, pancreatic intraepithelial neoplasias, and PDAC, in addition to pro

63 for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the Clinical

64 mucinous cystic neoplasms, while pancreatic intraepithelial neoplasias are rarely detected.

65 that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical carcinoma

66 n; the corresponding efficacies against anal intraepithelial neoplasia associated with HPV of any typ

67 quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associated with HPV-6, 11, 16,

68 Efficacy of the qHPV vaccine against anal intraepithelial neoplasia associated with HPV-6, 11, 16,

69 1 induced histological features of prostatic intraepithelial neoplasia at 7 months of age; these feat

70 ce exhibited metaplasia-associated prostatic intraepithelial neoplasia at a low frequency.

71 PRKD1(KO)-KC mice developed more pancreatic intraepithelial neoplasia, at a faster rate, than KC mic

72 fective in preventing recurrence from breast intraepithelial neoplasia but have a lower toxicity than

73 sulted in development of high-grade cervical intraepithelial neoplasia, but not frank cervical carcin

74 ally accelerated the progression of prostate intraepithelial neoplasia, by promoting cell proliferati

75 t epithelial atypia (controls); conjunctival intraepithelial neoplasia, carcinoma in situ (CIS); and

76 bout test performance for detecting cervical intraepithelial neoplasia (CIN) and cancer and screening

77 t the long-term yield of high-grade cervical intraepithelial neoplasia (CIN) and the influence on bio

78 (LEEP) for histologically confirmed cervical intraepithelial neoplasia (CIN) grade 2 or higher regard

79 re defined as women classified with cervical intraepithelial neoplasia (CIN) grade 2+ (CIN2+) (n = 10

80 We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2-3 and adenocarc

81 istory and histologically confirmed cervical intraepithelial neoplasia (CIN) in 2.5 years after the b

82 enic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current t

83 ous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) prevalence, incidence, p

84 To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adjusting fo

85 Comparison of conjunctival intraepithelial neoplasia (CIN) vs SCC revealed SCC with

86 rognostic test to ascertain whether cervical intraepithelial neoplasia (CIN) will regress or progress

87 specimens, including 38 normal, 52 cervical intraepithelial neoplasia (CIN), and 68 cervical cancer

88 hy, human papilloma virus (HPV) +/- cervical intraepithelial neoplasia (CIN), or cervical cancer.

89 or the identification of high-grade cervical intraepithelial neoplasia (CIN).

90 e followed semiannually for HPV and cervical intraepithelial neoplasia (CIN).

91 papillomavirus (HPV) infection, and cervical intraepithelial neoplasia (CIN); however, causal inferen

92 iruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers near the ec

93 ly increased with disease severity (cervical intraepithelial neoplasia [CIN] 3, 17.9% [+/-7.2] vs CIN

94 ated STAT3 increased from low-grade cervical intraepithelial neoplasia (CIN1) to precancerous CIN3 le

95 nning normalcy, increasingly severe cervical intraepithelial neoplasia (CIN1- CIN3), and cervical can

96 asma viral load (PVL) on high-grade cervical intraepithelial neoplasia (CIN2+) detection at follow-up

97 HC2 for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a total of 8,610 ce

98 span of progression from high-grade cervical intraepithelial neoplasia (CIN2/3) to invasive cervical

99 r the ability to predict high-grade cervical intraepithelial neoplasias (CIN2 or worse) in correspond

100 Overall, 28 high-grade cervical intraepithelial neoplasia (CIN3) cases were detected.

101 cidence rates (CIRs) of >/= grade 3 cervical intraepithelial neoplasia (CIN3+) or cancer for enrollme

102 Cervical dysplastic lesions called cervical intraepithelial neoplasias (CINs) need be treated to pre

103 rognostic test to ascertain whether cervical intraepithelial neoplasias (CINs) regress or progress.

104 Here, we show that pancreatic intraepithelial neoplasia driven by oncogenic mutant Kra

105 anogenital warts, oral warts, and anogenital intraepithelial neoplasias (eg, cervical intraepithelial

106 diagnosed cytologically; 1198 with cervical intraepithelial neoplasia grade 1 (CIN1), 456 with CIN2,

107 nst 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (CIN1+) ass

108 d with older age and a diagnosis of cervical intraepithelial neoplasia grade 1 or greater.

109 nst 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) asso

110 h channel based on the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or greater (>/=

111 , clinical performance in detecting cervical intraepithelial neoplasia grade 2 (CIN2) or more severe

112 ic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [<CIN2]) or cases (cer

113 t viral load, which varied by type (cervical intraepithelial neoplasia grade 2 [CIN2] for HPV52, CIN3

114 f a high-grade precancerous lesion (cervical intraepithelial neoplasia grade 2 or 3) or cervical canc

115 nce of high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma i

116 dy, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (CIN2/3; n

117 Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (CIN-2+; th

118 ainst 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (CIN2+) ass

119 Sensitivity of detecting cervical intraepithelial neoplasia grade 2 or greater in HIV-nega

120 types) were informative to predict cervical intraepithelial neoplasia grade 2 or greater.

121 the Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and

122 aginal samples for the detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+).

123 eoplasia grade 2 [<CIN2]) or cases (cervical intraepithelial neoplasia grade 2 or higher [CIN2+]) for

124 des 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplasia grade 2 or higher [CIN2+]) in

125 The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnos

126 amous intraepithelial lesion (HSIL) and anal intraepithelial neoplasia grade 2 or more severe diagnos

127 of doses administered, diagnoses of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) or gr

128 n have used the disease endpoint of cervical intraepithelial neoplasia grade 2 or worse (CIN2+).

129 for preventing HPV 16/18-associated cervical intraepithelial neoplasia grade 2 or worse (CIN2+).

130 ce in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in HPV-naive

131 ICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, regardless o

132 nclarity assay for the detection of cervical intraepithelial neoplasia grade 2+ (CIN2+) and CIN3+ was

133 Both assays detected >/=91.7% of cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions.

134 ons, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise

135 result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), including 43

136 lastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) compared to

137 low specificities for the detection of anal intraepithelial neoplasia grade 2/3 (AIN2/3) in this pop

138 We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or adenocar

139 uamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) i

140 s from patients with HPV-associated cervical intraepithelial neoplasia grade 2/3 and murine skin disp

141 vulvar cancer), and vaginal disease (vaginal intraepithelial neoplasia grade 2/3, vaginal cancer) rel

142 cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2/3, vulvar cancer), and

143 at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or worse over 5

144 bstudy was histologically confirmed cervical intraepithelial neoplasia grade 3 (CIN3) or worse.

145 alignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).

146 igibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 and at least one lesio

147 aseline specimens from 482 cases of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) and

148 Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n =

149 The primary endpoint was cervical intraepithelial neoplasia grade 3 or more severe (CIN3+)

150 topathologically confirmed CIN2+ or cervical intraepithelial neoplasia grade 3 or worse associated wi

151 ancer, 6.68 (95% CI, 3.64 to 12.25) for anal intraepithelial neoplasia grade 3, 4.97 (95% CI, 3.26 to

152 er, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial neoplasia grade 3, 86.08 (95% CI, 11.98

153 , 25.65 (95% CI, 10.50 to 62.69) for vaginal intraepithelial neoplasia grade 3, and 5.51 (95% CI, 1.2

154 was upregulated in patients with pancreatic intraepithelial neoplasias grade 3 and PDAC lesions rela

155 sts for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] or grade >

156 sts for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] or grade >

157 , anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3).

158 gnificance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+,

159 1 (HPV31) DNA loads and the risk of cervical intraepithelial neoplasia grades 2 and 3 (CIN2-3) was ev

160 We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma

161 We analyzed data on cervical intraepithelial neoplasia grades 2-3 and adenocarcinoma

162 % CI = 37.9 to 68.3) for diagnosing cervical intraepithelial neoplasia grades 2/3 (CIN2/3) on histolo

163 implemented mandatory reporting of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma

164 ble knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferatio

165 We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to indivi

166 precancerous anal lesions or high-grade anal intraepithelial neoplasia (HGAIN) have been vaccinated e

167 omavirus (HPV) genotypes-and high-grade anal intraepithelial neoplasia (HGAIN) in men who have sex wi

168 (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a

169 High-grade prostatic intraepithelial neoplasia (HGPIN) is considered a precur

170 among men with isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy.

171 be differentiated from high-grade prostatic intraepithelial neoplasia (HGPIN), a pre-malignant intra

172 uman prostate cancer and high-grade prostate intraepithelial neoplasia (HGPIN).

173 e, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN).

174 D2A resulted in the development of prostatic intraepithelial neoplasia in mice, demonstrating that JM

175 g a significant increase in the frequency of intraepithelial neoplasia in patients who received a lip

176 ntly accelerates the initiation of prostatic intraepithelial neoplasia in this model.

177 al activation entirely surrounded pancreatic intraepithelial neoplasias in KPC/Cdh11(+/+) mice and in

178 f the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, am

179 cally attenuates the formation of pancreatic intraepithelial neoplasia induced by mutant Kras(G12D),

180 normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive adenocarcinoma, or p

181 Prostatic intraepithelial neoplasia is a precursor to prostate can

182 Vulval intraepithelial neoplasia is a skin disorder affecting t

183 standard treatment for patients with vulval intraepithelial neoplasia is surgery, but this approach

184 was decoded from five grade 2 or 3 cervical intraepithelial neoplasia lesion (CIN2/3) samples and fi

185 ic introduction of an oncogene for prostatic intraepithelial neoplasia lesion development.

186 ramatic hyperplasia and multifocal prostatic intraepithelial neoplasia lesions from adjacent naive ep

187 eficient mice exhibited widespread prostatic intraepithelial neoplasia lesions in all prostatic lobes

188 ce and the replicative activity of prostatic intraepithelial neoplasia lesions in the dorsal prostate

189 l metaplasia (ADM)-a precursor of pancreatic intraepithelial neoplasia lesions that can progress to P

190 induction of NFATc2 in late-stage pancreatic intraepithelial neoplasia lesions with increased express

191 cumulate low-grade, pre-malignant pancreatic intraepithelial neoplasia lesions, but progression to hi

192 with development of premalignant pancreatic intraepithelial neoplasia lesions.

193 than reduced, number of low-grade pancreatic intraepithelial neoplasia (mPanIN) lesions.

194 is coexpressed with MUC1 in mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and in t

195 c-MYC-initiated cells progress to prostatic intraepithelial neoplasia (mPIN) and adenocarcinoma lesi

196 l transgenic mice developed murine prostatic intraepithelial neoplasia (mPIN) and prostatic adenocarc

197 le transgenic mice displayed mouse prostatic intraepithelial neoplasia (mPIN) in the ventral and dors

198 tive stroma activation surrounding prostatic intraepithelial neoplasia (mPIN) lesions found both in i

199 he transgenic mice displayed mouse prostatic intraepithelial neoplasia (mPIN) lesions.

200 ) in mice harboring oncogene-driven prostate intraepithelial neoplasia (mPIN).

201 psy-proved squamous cell carcinoma or vulvar intraepithelial neoplasia occurred during follow-up in 0

202 f diagnoses of anogenital warts and cervical intraepithelial neoplasia of grade 2 or 3 and cases of c

203 f diagnoses of anogenital warts and cervical intraepithelial neoplasia of grade 2 or 3 and cases of c

204 incident persistent qHPV infection, cervical intraepithelial neoplasia of grade 2 or higher [CIN2+],

205 of residual or recurrent high-grade cervical intraepithelial neoplasia of grade two or worse (CIN2+)

206 ry efficacy objective was prevention of anal intraepithelial neoplasia or anal cancer related to infe

207 s and 86.1% in women with NLIM (negative for intraepithelial neoplasia or malignancy) cytology who we

208 evels are associated with a history of prior intraepithelial neoplasia or pT1mic/pT1a breast cancer a

209 High-grade anal intraepithelial neoplasia or worse (HG-AIN+) was diagnos

210 at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to inva

211 e than those in therapy-naive PCa, prostatic intraepithelial neoplasia, or benign tissues.

212 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01).

213 stem (CNS) occurs as early as the pancreatic intraepithelial neoplasia (PanIN) 2 stage.

214 ), and KC(iMist1) mouse models of pancreatic intraepithelial neoplasia (PanIN) and analyzed by confoc

215 hat underwent ADM can progress to pancreatic intraepithelial neoplasia (PanIN) and eventually pancrea

216 A) develops predominantly through pancreatic intraepithelial neoplasia (PanIN) and intraductal papill

217 velopment and is induced in mouse pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal

218 d might be viewed as a prelude to pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal

219 ce of oncogenic KRAS, accelerates pancreatic intraepithelial neoplasia (PanIN) formation and the deve

220 ates acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia (PanIN) formation, and PanIN p

221 We previously demonstrated that pancreatic intraepithelial neoplasia (PanIN) formation, which prece

222 Increasing grade of pancreatic intraepithelial neoplasia (PanIN) has been associated wi

223 he earliest stages of preinvasive pancreatic intraepithelial neoplasia (PanIN) in the KrasLSL-G12D/+

224 hages contribute to fibrogenesis, pancreatic intraepithelial neoplasia (PanIN) lesion growth, and gen

225 progressively develop high-grade pancreatic intraepithelial neoplasia (PanIN) lesions and neoplasia

226 transition from early to advanced pancreatic intraepithelial neoplasia (PanIN) lesions, we assessed w

227 to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions.

228 ions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progresses to PDA

229 anc-28 cells and samples of human pancreatic intraepithelial neoplasia (PanIN), along with several bi

230 IS biomarkers in human and murine pancreatic intraepithelial neoplasia (PanIN), and found that only s

231 ed and analyzed for inflammation, pancreatic intraepithelial neoplasia (PanIN), and PDAC.

232 d kinase, inflammation, fibrosis, pancreatic intraepithelial neoplasia (PanIN), and PDACs.

233 ), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the a

234 C and its preinvasive precursors, pancreatic intraepithelial neoplasia (PanIN), arise via reprogrammi

235 ithelium accelerated formation of pancreatic intraepithelial neoplasia (PanIN), increased the frequen

236 ys, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC

237 scin deficiency on development of pancreatic intraepithelial neoplasia (PanIn), PDAC, and metastasis.

238 n is expressed in human and mouse pancreatic intraepithelial neoplasia (PanIN), suggesting that N-cad

239 creatic acinar cells give rise to pancreatic intraepithelial neoplasia (PanIN), the most common precu

240 of PDA and its precursor lesion, pancreatic intraepithelial neoplasia (PanIN), we examined the effec

241 Using a murine model of pancreatic intraepithelial neoplasia (PanIN), we found that Kras(G1

242 M proteins in normal pancreas and pancreatic intraepithelial neoplasia (PanIN)- and PDAC-bearing panc

243 , thus resisting the formation of pancreatic intraepithelial neoplasia (PanIN)-derived PDA.

244 ing initiation and development of pancreatic intraepithelial neoplasia (PanIN).

245 ise from precursor lesions termed pancreatic intraepithelial neoplasia (PanIN).

246 been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN).

247 ancies, including human PDACs and pancreatic intraepithelial neoplasia (PanIN).

248 ar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN).

249 asia (ADM) and its progression to pancreatic intraepithelial neoplasia (PanIN).

250 olves visualisation of high-grade pancreatic intraepithelial neoplasias (PanIN-3), generally regarded

251 olves visualization of high-grade pancreatic intraepithelial neoplasias (PanIN-3s), generally regarde

252 the formation and maintenance of pancreatic intraepithelial neoplasia (PanINs) in p48Cre; TetO-KrasG

253 cancer and initiate precancerous pancreatic intraepithelial neoplasia (PanINs) when induced in mouse

254 iation and expansion of low-grade pancreatic intraepithelial neoplasia (PanINs), likely through diffe

255 titute hallmark features of human pancreatic intraepithelial neoplasia (PanINs), the precursor to pan

256 sufficient to induce formation of pancreatic intraepithelial neoplasia (PanINs)-a precursor of PDAC.

257 tubular complexes (TC) and early pancreatic intraepithelial neoplasia (PanINs).

258 s the development of premalignant pancreatic intraepithelial neoplasias (PanINs) and cystic lesions i

259 ancreatic ductal adenocarcinomas, pancreatic intraepithelial neoplasias (PanINs) and normal pancreas

260 cinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasias (PanINs) and ultimately pancr

261 protected from the development of pancreatic intraepithelial neoplasias (PanINs).

262 EGLs) in men, including condyloma and penile intraepithelial neoplasia (PeIN).

263 Rates of anal intraepithelial neoplasia per 100 person-years were 17.5

264 infection is sufficient to enhance prostate intraepithelial neoplasia (PIN) and microinvasive carcin

265 ostate cancer model, as well as in prostatic intraepithelial neoplasia (PIN) before histological or a

266 s in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one

267 used tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice.

268 ed with development of premalignant prostate intraepithelial neoplasia (PIN) lesions and invasive ade

269 Further, prostatic intraepithelial neoplasia (PIN) progressed to carcinoma

270 d loss of Akap12 and Rb results in prostatic intraepithelial neoplasia (PIN) that fails to progress t

271 sed the prevalence and severity of prostatic intraepithelial neoplasia (PIN), a premalignant lesion.

272 sses: epithelium, stroma, atrophy, prostatic intraepithelial neoplasia (PIN), and prostate cancer Gle

273 s ductal hyperplasia and low-grade prostatic intraepithelial neoplasia (PIN).

274 controls, and eventually developed prostatic intraepithelial neoplasia (PIN).

275 en of early-stage prostate cancer [prostatic intraepithelial neoplasia (PIN)] and well-differentiated

276 enign prostatic hyperplasia [BPH], prostatic intraepithelial neoplasia [PIN], inflammation, and atrop

277 d densely methylated in high-grade prostatic intraepithelial neoplasia, primary prostate carcinoma, a

278 SL-KrasG12D model by exacerbating pancreatic intraepithelial neoplasias, promoting facial papillomas,

279 The rate of grade 2 or 3 anal intraepithelial neoplasia related to infection with HPV-

280 of the mucin family during early pancreatic intraepithelial neoplasia stage I (PanIN-I) of pancreati

281 nactivation of this GTPase at the pancreatic intraepithelial neoplasia stage promotes pancreatic tiss

282 that survivin interference at the prostatic intraepithelial neoplasia stages may be a potential ther

283 reater number and higher grade of pancreatic intraepithelial neoplasias than KC mice, and 1 mouse dev

284 ons (eg, epithelial hyperplasias and mammary intraepithelial neoplasias) than D1(-/-) females.

285 human pancreatic cancer cells and pancreatic intraepithelial neoplasia, the early lesion of pancreati

286 nic KRAS in both the formation of pancreatic intraepithelial neoplasias, the most common precursor le

287 PDAC tissues and in premalignant pancreatic intraepithelial neoplasia tissues isolated from Pdx-1-Cr

288 participates in the progression of prostatic intraepithelial neoplasia to adenocarcinoma, and that su

289 is required for the transition of prostatic intraepithelial neoplasia to frank adenocarcinoma.

290 ry of prostate cancer leading from prostatic intraepithelial neoplasia to invasive carcinoma.

291 HmC) in CAFs, in progression from pancreatic intraepithelial neoplasia to PDAC.

292 is an essential component of the pancreatic intraepithelial neoplasias-to-PDAC route in Kras(G12D)-d

293 d cancer is not suspected, usual-type vulvar intraepithelial neoplasia treatment, including medical a

294 n paraffin-embedded VSCC and adjacent vulvar intraepithelial neoplasia (VIN) and VLS specimens, in ca

295 increased dramatically when only pancreatic intraepithelial neoplasia were apparent.

296 syndrome, clonal hematopoiesis, and cervical intraepithelial neoplasia which also serve as models for

297 o early pancreatic lesions called pancreatic intraepithelial neoplasias, which are challenging to det

298 d acinar-to-ductal metaplasia and pancreatic intraepithelial neoplasias, which rapidly progressed to

299 r 3 years can halve the recurrence of breast intraepithelial neoplasia with a limited toxicity, which

300 rly neoplastic lesions (high-grade prostatic intraepithelial neoplasia) with striking nuclear atypia